JP2021513519A5 - - Google Patents

Info

Publication number
JP2021513519A5
JP2021513519A5 JP2020541908A JP2020541908A JP2021513519A5 JP 2021513519 A5 JP2021513519 A5 JP 2021513519A5 JP 2020541908 A JP2020541908 A JP 2020541908A JP 2020541908 A JP2020541908 A JP 2020541908A JP 2021513519 A5 JP2021513519 A5 JP 2021513519A5
Authority
JP
Japan
Prior art keywords
azabicyclo
hexane
amine
pyridazin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513519A (ja
JP7352294B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016300 external-priority patent/WO2019152809A1/en
Publication of JP2021513519A publication Critical patent/JP2021513519A/ja
Publication of JP2021513519A5 publication Critical patent/JP2021513519A5/ja
Application granted granted Critical
Publication of JP7352294B2 publication Critical patent/JP7352294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541908A 2018-02-02 2019-02-01 ムスカリン性アセチルコリン受容体m4のアンタゴニスト Active JP7352294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625656P 2018-02-02 2018-02-02
US62/625,656 2018-02-02
PCT/US2019/016300 WO2019152809A1 (en) 2018-02-02 2019-02-01 Antagonists of the muscarinic acetylcholine receptor m4

Publications (3)

Publication Number Publication Date
JP2021513519A JP2021513519A (ja) 2021-05-27
JP2021513519A5 true JP2021513519A5 (cg-RX-API-DMAC7.html) 2022-02-16
JP7352294B2 JP7352294B2 (ja) 2023-09-28

Family

ID=67480022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541908A Active JP7352294B2 (ja) 2018-02-02 2019-02-01 ムスカリン性アセチルコリン受容体m4のアンタゴニスト

Country Status (10)

Country Link
US (1) US11414406B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746421B1 (cg-RX-API-DMAC7.html)
JP (1) JP7352294B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200116945A (cg-RX-API-DMAC7.html)
CN (1) CN111788182B (cg-RX-API-DMAC7.html)
AU (1) AU2019216492A1 (cg-RX-API-DMAC7.html)
CA (1) CA3090130A1 (cg-RX-API-DMAC7.html)
IL (1) IL276411B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019152809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004638B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
US12319701B2 (en) 2019-10-04 2025-06-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CA3169667A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
CA3199724A1 (en) 2020-11-26 2022-06-02 Yusheng Xiong Anticholinergic agents

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US20040044029A1 (en) 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
AU2002347553A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1618091A1 (en) * 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006035280A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090176856A1 (en) * 2004-09-27 2009-07-09 Anita Mehta Muscarinic receptor antagonists
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
EP1904495A2 (en) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用
CN101230058A (zh) 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN103102352B (zh) 2011-11-15 2015-08-12 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
CA2903903C (en) * 2013-03-05 2021-05-04 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
HRP20210935T1 (hr) * 2014-05-23 2021-08-06 F. Hoffmann - La Roche Ag Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
JP6917989B2 (ja) 2015-11-06 2021-08-11 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 神経学的疾患を処置するためのムスカリン受容体4(m4)アンタゴニストとしての、n−[2−(1−ベンジルピペリジン−4−イル)エチル]−4−(ピラジン−2−イル)−ピペラジン−1−カルボキサミド誘導体および関連化合物
CA3119019C (en) * 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
BR112018016689A2 (pt) 2016-02-16 2019-02-12 Univ Vanderbilt moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
AU2018313802A1 (en) * 2017-08-08 2020-02-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019079410A1 (en) * 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
JP7270989B2 (ja) * 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
ES2982890T3 (es) * 2017-10-31 2024-10-18 Univ Vanderbilt Antagonistas del receptor muscarínico de acetilcolina M4
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS

Similar Documents

Publication Publication Date Title
JP2023123854A5 (cg-RX-API-DMAC7.html)
AU2019283921A1 (en) Indole carboxamide compounds useful as kinase inhibitors
TW444013B (en) Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia
JP2021500345A5 (cg-RX-API-DMAC7.html)
JP2022520448A5 (cg-RX-API-DMAC7.html)
IL273924B2 (en) Antagonists of the muscarinic acetylcholine receptor m4
RU2009136299A (ru) Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
JP2017533968A5 (cg-RX-API-DMAC7.html)
JP2009538910A5 (cg-RX-API-DMAC7.html)
JP2017125037A (ja) イミダゾピロリジノン化合物
JP2023536164A5 (cg-RX-API-DMAC7.html)
CA2883894A1 (en) Compounds and methods for kinase modulation, and indications therefor
JPH0219112B2 (cg-RX-API-DMAC7.html)
JP2001524116A (ja) 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体
CN107108588A (zh) 可用于治疗癌症的稠合双环(杂)芳香族化合物
CA2611530A1 (en) Tyrosine kinase inhibitors
CN107207531A (zh) 作为TGF‑β抑制剂的稠合的咪唑衍生物
CN104125947A (zh) 杂环脲化合物
WO2022140769A1 (en) Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
JP2025504916A5 (cg-RX-API-DMAC7.html)
JP2019537581A5 (cg-RX-API-DMAC7.html)
AU2021299200A1 (en) Processes for making SERD tricyclic compounds having a substituted phenyl or pyridinyl moiety
JP2023552838A5 (cg-RX-API-DMAC7.html)
JP7168245B2 (ja) 三環式化合物
AU2015212495A1 (en) Antibacterial combinations comprising polymyxin